证券代码：600521 证券简称：华海药业 公告编号：临 2025-126 号 债券代码：110076 债券简称：华海转债 浙江华海药业股份有限公司 关于"华海转债"可选择回售的第四次提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江华海药业股份有限公司（以下简称"公司"）的股票自 2025 年 11 月 2 日 至 2025 年 12 月 12 日连续 30 个交易日收盘价格低于公司可转换公司债券（以下 简称"华海转债"）当期转股价格的 70%。根据《浙江华海药业股份有限公司公开 发行可转换公司债券募集说明书》（以下简称"《募集说明书》"）的约定，可转债 回售条款生效。 现依据《上市公司证券发行管理办法》《可转换公司债券管理办法》《上海证 券交易所股票上市规则》和《募集说明书》等有关规定，就回售有关事项向全体 "华海转债"持有人公告如下： 一、回售条款 1 / 3 回售价格：100.30 元人民币/张（含当期利息、含税） 回售期：2025 年 12 月 22 日至 2025 年 12 月 26 ...

Core Viewpoint - The company announces the right for holders of "Huahai Convertible Bonds" to sell back part or all of their unconverted bonds under specific conditions, with a buyback price set at RMB 100.30 per bond, including accrued interest and tax [1][4][10]. Group 1: Buyback Terms - Holders of "Huahai Convertible Bonds" can exercise their right to sell back the bonds if the company's stock price remains below 70% of the conversion price for 30 consecutive trading days during the last two interest years of the bond [2][6]. - The buyback price is calculated to include accrued interest, which for the sixth year at a coupon rate of 2.00% over 54 days amounts to approximately RMB 0.30 per bond, leading to a total buyback price of RMB 100.30 [5][10]. Group 2: Buyback Period and Procedures - The buyback period is set from December 22, 2025, to December 26, 2025, with funds to be disbursed on December 31, 2025 [4][11]. - During the buyback period, "Huahai Convertible Bonds" will continue to trade but will not be convertible into shares [13]. Group 3: Additional Information - If the total face value of the bonds in circulation falls below RMB 30 million due to the buyback, trading will continue until the end of the buyback period, after which an announcement will be made [13]. - The company will disclose the results of the buyback and its impact on the company after the buyback period concludes [12].

关于"华海转债"可选择回售的第三次提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600521 证券简称：华海药业 公告编号：临 2025-125 号 债券代码：110076 债券简称：华海转债 浙江华海药业股份有限公司 重要内容提示： 浙江华海药业股份有限公司（以下简称"公司"）的股票自 2025 年 11 月 2 日 至 2025 年 12 月 12 日连续 30 个交易日收盘价格低于公司可转换公司债券（以下 简称"华海转债"）当期转股价格的 70%。根据《浙江华海药业股份有限公司公开 发行可转换公司债券募集说明书》（以下简称"《募集说明书》"）的约定，可转债 回售条款生效。 现依据《上市公司证券发行管理办法》《可转换公司债券管理办法》《上海证 券交易所股票上市规则》和《募集说明书》等有关规定，就回售有关事项向全体 "华海转债"持有人公告如下： 一、回售条款 1 / 3 回售价格：100.30 元人民币/张（含当期利息、含税） 回售期：2025 年 12 月 22 日至 2025 年 12 月 26 ...

Group 1: Monetary Policy and Economic Outlook - The monetary policy in 2026 will continue to align with fiscal measures, supporting debt sustainability and fiscal health [2][12] - Interest rate cuts in 2026 may remain restrained due to reduced urgency from anti-involution trends, with a higher probability of one rate cut rather than two [2][12] - The international economic struggle will have financial implications, particularly for the internationalization of the RMB amid intensified US-China competition [2][12] Group 2: Misunderstandings about "Deposit Migration" - There are three main misunderstandings regarding "deposit migration": underestimating excess savings, the speed of market entry, and the investment attributes of excess savings [3][14] - The potential scale of excess savings is estimated to exceed 9.4 trillion, indicating significant funds could enter the stock market [3][14] - The speed of funds entering the market may be underestimated due to reliance on non-bank deposit tracking, which does not accurately reflect the migration of resident funds [3][14] Group 3: Huahai Pharmaceutical (600521) Analysis - Huahai Pharmaceutical is a leading domestic producer of specialty APIs, with a strong focus on global formulation strategies [4][13] - The company has applied for over 70 domestic and international patents in the field of biopharmaceuticals, particularly in immunology and oncology [4][17] - The projected revenue for Huahai Pharmaceutical from 2025 to 2027 is expected to be 8.632 billion, 9.413 billion, and 10.282 billion respectively, with a target market value indicating a potential upside of 30.04% [4][17]

Group 1: Monetary Policy and Economic Outlook - The monetary policy in 2026 will continue to align with fiscal measures, supporting debt sustainability and fiscal health [2] - Interest rate cuts in 2026 may remain restrained due to reduced urgency from anti-involution trends [2] - The international economic struggle will have financial implications, particularly for the internationalization of the RMB amid intensified US-China tensions [2][13] Group 2: Misunderstandings about "Deposit Migration" - There are three main misunderstandings regarding "deposit migration": underestimating excess savings, the speed of market entry, and the investment attributes of excess savings [3][15] - The potential scale of household savings entering the stock market could exceed one trillion yuan, driven by a significant increase in excess savings [3][15] - The speed of funds entering the market may be underestimated due to reliance on non-bank deposit tracking, which does not accurately reflect the migration of household funds [3][15] Group 3: Huahai Pharmaceutical (600521) Insights - Huahai Pharmaceutical integrates raw materials and formulations, establishing a solid foundation for growth, with a projected revenue of 5.759 billion yuan in 2024 [4][14] - The company is focusing on innovative drug development in immunology and oncology, with over 70 patents filed and several projects in clinical stages [4][18] - The target market capitalization for Huahai Pharmaceutical is estimated at 34.4 billion yuan, indicating a potential upside of 30.04% [4][18] Group 4: Zhongxin Innovation (03931) Overview - Zhongxin Innovation is positioned to benefit from the growing demand for energy storage and electric vehicle batteries, with a revenue of 16.4 billion yuan in the first half of 2025 [19][20] - The company is expanding its market share and enhancing its product offerings, with a focus on high-end battery products and a global production network [19][20] - The projected net profit for Zhongxin Innovation is expected to grow significantly, reaching 3.84 billion yuan by 2027 [20]

Core Viewpoint - Jiuzhou Pharmaceutical is entering a growth phase driven by its CDMO platform, which leverages its expertise in small molecules and TIDES, supported by a healthy project pipeline and high order visibility [3][5]. CDMO Business - The CDMO business is the main growth engine, with a robust project funnel and high order visibility. The company provides comprehensive lifecycle services from preclinical CMC to commercial production, deeply embedded in the supply chains of major pharmaceutical companies like Novartis and Roche [3]. - Key projects such as Noxafil and Ribociclib continue to generate revenue, while the rapid growth of the partnered product Vumerity is expected to provide sustained incremental growth [3]. - As of H1 2025, the company has a rich pipeline with 38 products on the market, 90 in Phase III, and 1,086 in Phase I/II, driving steady revenue growth [3]. API Business - The company focuses on specialty APIs, optimizing processes to enhance cost advantages. It holds a strong position in the CNS and anti-infection specialty API markets [4]. - Core product prices are expected to improve as industry inventory depletion nears completion, while new product categories are being introduced, including four specialty APIs by 2025 [4]. - Continuous process optimization and reduced development cycles are helping to maintain cost advantages, with an API business gross margin of 23.26% in H1 2025, up 2.08 percentage points year-on-year [4]. Formulations and CDMO - The company has made significant strides in its formulation and CDMO business through acquisitions and the establishment of its own facilities, completing its layout for generic and innovative drug formulations [4]. - As of Q3 2025, the formulation pipeline includes 22 projects, with 8 approved and 9 submitted for approval. The CDMO business has onboarded over 10 high-quality domestic and international clients, adding more than 30 new service projects [4]. - The formulation business is expected to maintain rapid growth in the future [4]. Investment Recommendation - The company has established a one-stop CDMO platform covering small molecules, peptides, conjugates, and formulations, serving major global pharmaceutical companies and achieving localized R&D in the US, Japan, and Germany [5]. - Projected net profits for 2025-2027 are estimated at 966 million, 1.128 billion, and 1.303 billion yuan, representing year-on-year growth of 59.4%, 16.8%, and 15.4% respectively [5]. - The current stock price corresponds to PE ratios of 16, 14, and 12 for 2025-2027. Given the company's growth prospects and strong order visibility, a target price of 26.64 yuan is set, with an initial "recommend" rating [5].

Core Viewpoint - The "Precision Radiotherapy for Depression" project aims to advance clinical research and application breakthroughs in treating depression using new generation precision radiotherapy technology, specifically the ZAP-X system, which is currently in the clinical research phase focusing on safety and efficacy [1] Group 1: Market Overview - Depression is one of the most common mental disorders globally, with approximately 332 million people affected, including over 90 million in China, of which 10 to 12 million require treatment during depressive episodes [1] - The antidepressant market in China is highly competitive, with SSRIs and SNRIs accounting for about 60% of the market share. The sales revenue for antidepressants in sample hospitals is expected to exceed 8 billion yuan in 2024, with SSRIs contributing 3.58 billion yuan (43.44%) and SNRIs 1.42 billion yuan (17.18%) [3][4] - The global antidepressant market was valued at approximately $14.5 billion in 2022 and is projected to reach $17.6 billion by 2030, with China's market expected to grow to 23.8 billion yuan by 2030, reflecting a compound annual growth rate (CAGR) of 4.2% from 2022 to 2030 [3][4] Group 2: Innovation and Development - There is a significant unmet clinical need as about 30% of patients do not respond to existing antidepressants, highlighting the potential of neuromodulation technologies as a complementary treatment, especially for treatment-resistant depression (TRD) [6] - Non-invasive neuromodulation techniques, such as transcranial magnetic stimulation (TMS), are gaining traction in clinical settings. TMS has been FDA-approved for depression treatment since 2008, and several certified TMS systems are available globally [7] - The "Precision Radiotherapy for Depression" project focuses on exploring the clinical efficacy and safety of low-dose radiotherapy for treatment-resistant depression, aiming to establish a new neuromodulation method with high precision targeting [9][10] Group 3: Research and Clinical Trials - The project is part of a broader trend in the development of innovative antidepressant therapies, with numerous new drugs in clinical trials targeting various mechanisms [4][5] - The project aims to investigate the potential of radiotherapy as a neuromodulation method, traditionally used for brain tumors, to treat depression, with initial studies showing promising results [10] - Collaboration among various professionals and addressing regulatory, funding, and resource challenges are crucial for the project's success and eventual commercialization [11]

证券代码：600521 证券简称：华海药业 公告编号：临 2025-124 号 债券代码：110076 债券简称：华海转债 浙江华海药业股份有限公司 关于"华海转债"可选择回售的第二次提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江华海药业股份有限公司（以下简称"公司"）的股票自 2025 年 11 月 2 日 至 2025 年 12 月 12 日连续 30 个交易日收盘价格低于公司可转换公司债券（以下 简称"华海转债"）当期转股价格的 70%。根据《浙江华海药业股份有限公司公开 发行可转换公司债券募集说明书》（以下简称"《募集说明书》"）的约定，可转债 回售条款生效。 现依据《上市公司证券发行管理办法》《可转换公司债券管理办法》《上海证 券交易所股票上市规则》和《募集说明书》等有关规定，就回售有关事项向全体 "华海转债"持有人公告如下： 一、回售条款 1 / 3 回售价格：100.30 元人民币/张（含当期利息、含税） 回售期：2025 年 12 月 22 日至 2025 年 12 月 26 ...

浙江华海药业股份有限公司 | 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 2025-123 号 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 关于公司及下属子公司涉及诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 案件所处的诉讼阶段：Gaston Roberts（以下简称"原告"或"上诉人"） 人身损害赔偿案件（以下简称"Gaston Roberts 案件"），原告就一审驳回原告起 诉的简易判决提起上诉。 上市公司及其子公司所处的当事人地位：被上诉人。 涉诉金额：上诉人未明确具体金额。 月 31 日刊登在中国证券报、上海证券报、证券时报、证券日报及上海证券交易 所网站（www.sse.com.cn）上的《浙江华海药业股份有限公司关于公司及其下属 子公司涉及诉讼的公告》（公告编号：临 2018-088 号）、《浙江华海药业股份有限 公司关于公司及其下属子公司涉及诉讼的补充公告》（公告编号：临 ...

Core Viewpoint - Huahai Pharmaceutical announced that the plaintiff in the Gaston Roberts personal injury compensation case has appealed the judgment that dismissed the lawsuit, with the company as the appellee. The amount involved in the appeal has not been specified. The appeal process has just begun and is in its early stages, making it difficult for the company to assess the impact on its financial results, which will depend on subsequent court rulings or enforcement outcomes. Aside from this case, there are no significant developments in other valsartan lawsuits in the U.S., and the outcomes remain uncertain [1]. Group 1 - The plaintiff in the Gaston Roberts case has appealed the dismissal of the lawsuit [1] - The company is currently unable to determine the financial impact of the appeal [1] - There are no significant updates on other valsartan lawsuits in the U.S. [1]